PitchBook's H1 2026 Healthcare IT PE Update landed this week. The headline is bullish: 442 deals projected for the full year, surpassing the post-COVID free-money peak. The subtext — buried in the RCM section — is the most important thing the revenue cycle industry has read in years.
PitchBook recorded 175 healthcare IT PE deals in the first half of 2026. Adjusted for reporting lag, their estimated deal count hits 221 — an annualized run rate of 442 transactions. That would surpass the 2021 peak of 424 deals, which was widely dismissed as a bubble inflated by zero interest rates and stimulus capital.
This time, the engine is different. It's agentic AI — not cheap money.
Projected 2026 healthcare IT PE deal count — would surpass the 2021 record of 424
Projected 2026 deal value, up 10.7% over 2025's $47.8B total
Trailing 12-month deal count growth year-over-year
2025 median TEV/EBITDA — well above the 13.3x average since 2015. AI-native assets command a premium above that.
The headline transaction in H1 was Thoreau Group's strategic growth investment in Ensemble Health Partners — a leading end-to-end RCM company — at a reported but unconfirmed $12 billion valuation. Ensemble had already run a $4.8 billion dividend recapitalization in February 2026, so this deal arrived on top of significant existing leverage. The largest single transaction was the $7.5 billion LBO of EGYM by Affinity Partners, Temasek, L Catterton, and Mindbody.
Provider operations led all segments with an estimated 108 transactions in H1 — on pace to grow 18% over 2025. The thesis driving those investments is uniform: agentic AI and workflow automation designed to eliminate administrative labor inside provider organizations.
| Segment | H1 2026 Deals | Count vs. 2025 | Value vs. 2025 |
|---|---|---|---|
| Provider Operations | 108 est. | +18% | +14.3% |
| Clinical Information Systems | 54 est. | +31.8% | -26.1% |
| Managed Care | 33 est. | +25.6% | +64.9% |
| Analytics & VBC | — | -42.7% | -46.1% |
| Virtual & Remote Care | — | -4.6% | -29.4% |
The clinical information systems number is worth parsing: volume up 32%, deal value down 26%. That's not momentum — that's a land-grab at compressed valuations, the kind of activity that happens when investors believe a category is about to be disrupted and want exposure before it reprices. Smaller bets, more of them.
Managed care at +64.9% deal value growth is the cleanest signal. Payor-side AI — prior auth automation, claims adjudication, utilization management — is attracting premium capital. That pressure lands directly on providers.
Deal counts down 42.7%, deal value down 46.1%. Value-based care infrastructure — the build-out that dominated the 2019–2022 cycle — is being defunded by PE. The capital is moving to automation plays. Standalone analytics vendors without agentic workflow integration are getting priced out of the market.
PitchBook buries the lead, but the lead is unmistakable: they think the RCM industry is about to be gutted.
Here is their language, verbatim:
"We believe revenue cycle management investments in aggregate will lead to significant value destruction over a typical PE investment horizon as competition accelerates from all angles... We expect take rates to compress by more than 80% and industry revenue to shrink by more than 50% by 2040."
They're not talking about the macro environment. They're talking about structural collapse of the RCM business model. Their specific claims:
The CommonSpirit Health / Conifer Health Solutions situation is cited directly. CommonSpirit terminated its Conifer contract early. That's not a routine vendor swap — that's a health system deciding its RCM partner is replaceable. It signals that the "sticky, long-term contract" protection that RCM vendors have relied on for a decade is starting to erode.
Thoreau Group's investment in Ensemble at a reported $12 billion is interesting precisely because PitchBook is simultaneously calling for value destruction in RCM. The answer to that apparent contradiction is timing.
Ensemble is the largest pure-play end-to-end RCM operator in the country. It processes revenue cycles for some of the largest health systems. At $12 billion, Thoreau is betting that Ensemble is either (a) positioned to become the agentic AI platform that survives consolidation, or (b) an acquisition target for a scaled technology company — Oracle, Microsoft, or an EHR vendor — that wants to own the RCM layer entirely.
Neither of those scenarios is bullish for the 300+ smaller RCM vendors below Ensemble in the market. The consolidation creates a two-tier market: heavily capitalized AI-native platforms at the top, and point-solution vendors being priced into obsolescence from below.
PitchBook's clearest structural observation: "The boundaries separating electronic health records (EHRs), clinical documentation, clinical decision support, data and analytics, and RCM are rapidly converging as vendors expand beyond their historical domains. Rather than competing within discrete software categories, vendors are increasingly competing to become the integrated intelligence layer embedded within clinical workflows." That's the end of RCM as a category. It becomes a capability inside something larger.
Three things to take from this report:
1. The PE capital pouring into healthcare IT is not coming to rescue your team's workflow problems — it's coming to eliminate them. When PitchBook says "agentic AI and workflow automation technologies designed to reduce administrative burden," they mean headcount reduction. Every dollar going into provider operations PE right now is a bet that human-driven billing and coding labor costs collapse.
2. Your RCM vendor's strategic position matters more than it did two years ago. The vendors that survive the next decade are the ones building toward integrated intelligence — not the ones adding AI features on top of legacy workflow tools. Ask your vendors where their product roadmap is heading and whether it connects to clinical documentation and EHR workflow, not just billing queues.
3. Cost-to-collect compression is coming whether or not your organization adopts AI. If the market moves from 4–5% to sub-1% — even partially — the economics of outsourced RCM change dramatically. Internal RCM operations with high fixed labor costs are exposed. The argument for outsourcing changes when the outsource vendor is fighting for margin survival.
PitchBook titled their companion report "AI Kills the RCM Star." That's not a prediction. It's a process already underway.
Payor policy shifts, PE moves, AI vendor changes — before they hit your A/R. Free for revenue cycle teams.